New Cholesterol Treatment 2026: First Oral PCSK9 Drug Approved

New Cholesterol Treatment 2026: First Oral PCSK9 Drug Approved to Lower LDL Cholesterol

A major development in cholesterol treatment has arrived in 2026. The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor designed to significantly reduce LDL (“bad”) cholesterol.

The approval provides doctors and patients with a new oral option for people who need additional LDL cholesterol lowering despite lifestyle changes and existing cholesterol medicines.

What Is the New Cholesterol Treatment?

Lipfendra, also known by its generic name enlicitide, is a once-daily oral medication that targets PCSK9, a protein involved in the regulation of LDL cholesterol.

Unlike injectable PCSK9 medicines, enlicitide is taken as a tablet, potentially making PCSK9-targeted treatment more convenient for some patients.

The FDA approved enlicitide in July 2026 as an addition to diet and exercise for adults with hypercholesterolemia, including people with certain forms of familial hypercholesterolemia.

How Does Enlicitide Work?

To understand how the drug works, it helps to understand PCSK9.

The liver removes LDL cholesterol from the bloodstream using LDL receptors. PCSK9 can cause these receptors to be broken down, reducing the liver's ability to clear LDL cholesterol.

Enlicitide inhibits PCSK9. This allows more LDL receptors to remain available on liver cells, increasing the removal of LDL cholesterol from the blood.

The result is a substantial reduction in LDL-C levels.

How Much Can the New Drug Lower LDL Cholesterol?

Clinical trials showed that enlicitide can produce a substantial reduction in LDL cholesterol.

In two randomized clinical trials involving more than 3,200 adults, enlicitide reduced LDL-C by approximately 56% to 59% at 24 weeks, compared with placebo, depending on the patient population.

This degree of LDL lowering is particularly important for people who have very high cholesterol or remain above their recommended LDL-C level despite other treatment.

Who May Need This New Cholesterol Medicine?

Enlicitide is not intended to replace healthy lifestyle habits or automatically replace statins.

Doctors may consider additional LDL-lowering treatment for patients who:

Have established atherosclerotic cardiovascular disease (ASCVD)

Have very high LDL cholesterol

Have familial hypercholesterolemia

Remain above their LDL-C goal despite maximally tolerated statin therapy

Cannot tolerate adequate doses of statins

Need substantial additional LDL reduction based on their cardiovascular risk

The appropriate treatment depends on the individual's cardiovascular risk, LDL-C level, medical history and response to previous therapy.

Is Enlicitide Better Than Statins?

Not necessarily.

Statins remain a cornerstone of cholesterol treatment. They have extensive evidence showing that lowering LDL cholesterol reduces the risk of heart attack and stroke.

The importance of enlicitide is that it adds another option for patients who need more LDL reduction.

Depending on the patient, doctors may use a combination of treatments such as:

Statins

Ezetimibe

Bempedoic acid

PCSK9-targeting therapies

Other lipid-lowering treatments

The choice should be individualized rather than assuming that the newest medication is automatically the best option.

Oral PCSK9 Drug vs Injectable PCSK9 Treatment

One of the most notable features of enlicitide is its oral route of administration.

Traditional PCSK9-targeting medicines such as monoclonal antibodies are administered by injection. An oral PCSK9 inhibitor could offer an alternative for patients who prefer tablets or have difficulty with injectable medications.

However, long-term clinical experience and real-world data will be important in determining how the new treatment fits into routine cholesterol management.

What About the New 2026 Cholesterol Guidelines?

The 2026 ACC/AHA dyslipidemia guideline places renewed emphasis on achieving appropriate LDL-C levels according to cardiovascular risk.

The guideline also highlights the importance of:

Measuring lipoprotein(a), or Lp(a), at least once during adulthood

Selective use of Apolipoprotein B (ApoB) testing

Using coronary artery calcium (CAC) scoring in appropriate patients to improve cardiovascular risk assessment

Using evidence-based lipid-lowering therapy to reduce cardiovascular risk

These developments reflect a broader shift toward more individualized cholesterol management.

What Are the Side Effects?

As with any prescription medicine, enlicitide can cause adverse effects.

The FDA-approved prescribing information should be consulted for the complete safety profile, contraindications, warnings and drug-interaction information.

Patients should not start, stop or change cholesterol medication without discussing it with their healthcare professional.

Can Lifestyle Changes Still Lower Cholesterol?

Absolutely.

Even with newer medications, lifestyle remains an important part of cholesterol management.

Helpful measures include:

Eating more vegetables, fruits, whole grains and high-fiber foods

Limiting saturated and trans fats

Maintaining a healthy body weight

Exercising regularly

Avoiding tobacco exposure

Managing diabetes and blood pressure

Taking prescribed cholesterol medication consistently

For people at high cardiovascular risk, lifestyle changes and medication often work together rather than being alternatives.

Why This New Cholesterol Drug Matters

The arrival of an oral PCSK9 inhibitor represents an important development in lipid management.

For decades, statins have been the mainstay of LDL cholesterol treatment. Additional medications have expanded the options available to patients who require greater LDL reduction.

Now, an oral PCSK9-targeting treatment provides another potential tool for clinicians.

The biggest question will be how enlicitide performs over time in routine clinical practice, including its long-term cardiovascular outcomes, safety, affordability and accessibility.

Frequently Asked Questions

What is the new cholesterol drug in 2026?

Enlicitide (Lipfendra) is a newly approved oral PCSK9 inhibitor for lowering LDL cholesterol.

Is enlicitide a statin?

No. Enlicitide is a PCSK9 inhibitor, not a statin.

Is enlicitide taken by mouth?

Yes. It is an oral, once-daily treatment.

How much can enlicitide lower LDL cholesterol?

Clinical trials reported approximately 56% to 59% LDL-C reductions at 24 weeks, depending on the study population.

Does everyone with high cholesterol need this new medication?

No. Treatment depends on LDL-C levels, cardiovascular risk, existing cardiovascular disease, familial hypercholesterolemia, response to other treatments and medication tolerance.

Are statins still recommended?

Yes. Statins remain a fundamental treatment for reducing cardiovascular risk in appropriate patients.

Bottom Line

The approval of enlicitide (Lipfendra) marks a significant new chapter in cholesterol treatment. As the first oral PCSK9 inhibitor, it offers a new approach to substantially lowering LDL cholesterol without requiring an injectable PCSK9 antibody.

However, the medication should be viewed as part of a broader cholesterol-management strategy. For many patients, lifestyle modification and statin therapy remain central, while additional medications may be added when LDL cholesterol remains above the recommended level.

Patients should discuss their individual LDL-C target and treatment options with their healthcare professional before changing cholesterol medication.

Medical disclaimer: This article is for educational purposes only and does not replace individualized medical advice, diagnosis or treatment from a qualified healthcare professional.